Aldeyra Therapeutics, Inc. (ALDX) stock
ALDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.84+0.12 (+16.39%)
Close on Nov 20, 2026Market cap $50.67MP/E –Yield –
Aldeyra Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Aldeyra Therapeutics's free cash flow for the twelve months ending Dec 31, 2023 was -$30.33M. For fiscal 2023 it was -$30.33M. The highest annual figure on record is -$4.79M in fiscal 2014.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$30.33M | – |
| FY2022 | Dec 31, 2022 | -$56.65M | – |
| FY2021 | Dec 31, 2021 | -$42.56M | – |
| FY2019 | Dec 31, 2019 | -$44.99M | – |
| FY2018 | Dec 31, 2018 | -$30.12M | – |
| FY2017 | Dec 31, 2017 | -$19.25M | – |
| FY2016 | Dec 31, 2016 | -$15.16M | – |
| FY2015 | Dec 31, 2015 | -$9.40M | – |
| FY2014 | Dec 31, 2014 | -$4.79M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | $500.44K | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.02M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.36M | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.44M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.23M | – |
| Q3 FY2022 | Sep 30, 2022 | -$12.57M | – |
| Q2 FY2022 | Jun 30, 2022 | -$19.96M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.89M | – |
| Q4 FY2021 | Dec 31, 2021 | -$11.58M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.43M | – |
| Q2 FY2021 | Jun 30, 2021 | -$9.07M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.48M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.24M | – |
| Q4 FY2019 | Dec 31, 2019 | -$11.23M | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.32M | – |
| Q2 FY2019 | Jun 30, 2019 | -$12.82M | – |
| Q1 FY2019 | Mar 31, 2019 | -$12.64M | – |
| Q4 FY2018 | Dec 31, 2018 | -$7.98M | – |
| Q3 FY2018 | Sep 30, 2018 | -$7.74M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.03M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.71M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.31M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.20M | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.91M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.50M | – |
| Q2 FY2016 | Jun 30, 2016 | -$3.26M | – |
See a number that looks wrong?